NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JRCT ID: jRCTs061200039

Registered date:25/12/2020

Examination of safety of oxytocin for patients with Alzheimer's disease dementia.

Basic Information

Recruitment status Recruiting
Health condition(s) or Problem(s) studiedAlzheimer disease dementia
Date of first enrollment25/12/2020
Target sample size20
Countries of recruitment
Study typeInterventional
Intervention(s)Oxytocin nasal spray, 24 IU once, twice daily for 8 days

Outcome(s)

Primary OutcomeHarmful reduction
Secondary Outcome1. dropout rate 2. NPI (Neuropsychiatric Inventory) 3. AES (Apathy Evaluation Scale) 4. VI (Vitality index) 5. ToM (Theory of Mind) 6. ACE-III (Addenbrooke's Cognitive Examination III) 7. ZBI (Zarit Burden Interview) 8. QOL-D (Quality of life questionnaire for dementia) 9. WHO-QOL (WHO Quality of Life) 10. blood levels of oxytocin 11. Vital Signs

Key inclusion & exclusion criteria

Age minimum>= 50age old
Age maximum<= 80age old
GenderBoth
Include criteria1. Over 50 years old, under 80 years old 2. In case that we obtain written informed consent from both the subjects and their guardian, or in case that we confirm their assent from the subjects and obtain written informed consent from their guardian 3. Diagnosed as dementia based on the ICD-10 and DSM-5 criteria 4. Diagnosed as Alzheimer's dementia based on the NIA-AA criteria 5. The Clinical Dementia Rating (CDR) is 0.5 or 1.0. 6. Those who lives with a family member and the family member can confirm and record whether the subjects use the intranasal oxytocin as defined during the study period
Exclude criteria1. Unstable psychiatric symptoms (NPI "agitation/aggression" severity of 2 or more) 2. Socially inappropriate sexual behavior 3. History of changing the psychotropic medication within a month 4. Currently under treatment with two or more psychotropic medications 5. History of oxytocin use within 6 months 6. History of hypersensitivity to oxytocin or latex 7. History of loss of consciousness 8. History of alcohol related disorder or substance abuse 9. History of myocardial infarction within 6 months 10. Uncontrolled hypertension 11. Bradycardia (< 50bpm) 12. Prolonged QT interval (> 0.45sec) 13. Hyponatremia (<136 mEq/L) 14. Pregnant or lactating women 15. Currently under treatment for or have a history of gynecological disease 16. Currently under treatment for endocrine disease 17. Currently under treatment for cardiovascular disease 18. Currently under treatment with steroids 19. Currently under treatment with prostaglandin 20. Currently under treatment with cyclophosphamide 21. History of participation in other clinical trials within 6 months 22. History of malignancy within 5 years 23. MRI cannot be administered 24. Judged by researcher that participation in research is not in the best interest of the research subject, or the participation of the subject interfere or confuse plan-specific assessments 25. Investigators who are directly involved in this research or other clinical studies, or employees of conducting medical institutions, or families of such employees or investigators

Related Information

Contact

Public contact
Name Shintaro TAKENOSHITA
Address 2-5-1 Shikata-cho, Kita-ku, Okayama Okayama Japan 700-8558
Telephone +81-86-235-7242
E-mail shintaro.take@gmail.com
Affiliation Okayama University Hospital
Scientific contact
Name Seishi TERADA
Address 2-5-1 Shikata-cho, Kita-ku, Okayama Okayama Japan 700-855
Telephone +81-86-235-7242
E-mail terada@okayama-u.ac.jp
Affiliation Okayama University Hospital